The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).
The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).
The position statement explains that the Swiss regulatory body, Swissmedic, requires that biosimilars be “sufficiently similar” in their structure, activity, efficacy, safety, and immunogenicity, much like the FDA’s requirement that there be no clinically meaningful differences between biosimilars and their references.
The statement goes on to say that biosimilars and biologics should be prescribed by brand name, not by international nonproprietary name (INN), because biosimilars and their reference products share INNs. Using brand names will help with postmarketing studies and monitoring programs, says the group, and global harmonization on nomenclature is desirable.
With respect to interchangeability of biosimilars with their reference products, the statement indicates that the infliximab biosimilars Inflectra and Remsima, which are the same product (CT-P13) marketed under different names, can be interchanged. The group cautions that interchanging the reference infliximab, Remicade, with biosimilars will require close monitoring for efficacy and safety.
The group strongly discourages pharmacy-level substitution, in keeping with Swissmedic’s advice that the decision to interchange products be left with prescribing physicians. “There is general concern that automatic substitution might lead to dispensing mistakes that might potentially harm patients, especially when interchangeability has not directly been demonstrated in many specific clinical settings of a given disease,” say the position statement’s authors, who add that concerns exist about pharmacovigilance, as pharmacists in Switzerland are not required to track batches of products, while prescribers must track such data.
Despite its cautions about interchangeability and substitution, the position does note that the available data on nonmedical switches from Remicade to CT-P13 do not suggest that there are adverse impacts related to switching. It also notes that immunogenicity and the frequency of adverse events have not been shown to differ between patients treated with reference or biosimilar infliximab.
However, the position also points out that, in Switzerland, unlike many other countries, healthcare providers “are currently the only beneficiaries of switching a patient from a reference product to a less-expensive biosimilar,” and patients do not see any financial benefit from undertaking a nonmedical switch. As such, nonmedical switches should be avoided, says the group.
Reference
Burri E, Juillerat P, Maillard MH, et al. Position statement on the use of biosimilars in inflammatory bowel disease. Swiss Med Wkly. 2019;149:w20148. doi: 10.4414/smw.2019.20148.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).